MedPharm || طبصيدلة
前往频道在 Telegram
شرح مادة الصيدلة السريرية clinical pharmacology 🧑🏻⚕️ معرف التلي: mohammedsalim10 Instagram: _a1mh
显示更多未指定国家未指定类别
3 511
订阅者
-224 小时
-157 天
-5830 天
帖子存档
3 511
Regarding the prostate cancer, Advanced Disease terized by all of the following,
EXCEPT:
3 511
A 64-year-old man with newly diagnosed metastatic prostate cancer presents to the clinic. Which of the following would be considered standard first-line therapy?
3 511
Adnan, 55-year-old, was diagnosed with prostate cancer and undergone prostatectomy. He may experience all the followings complications after the surgery EXCEPT:
-
3 511
58 years old man (life expectancy is about 20 years) who suffers from urinary frequency and hesitancy. He was diagnosed to have stage 3 prostate cancer. A biopsy was obtained and Gleason score was 8. Lab data shows prostate specific antigen of 30ng/ml. The patient has a medical history of osteoarthritis and celiac disease. Initial treatment for this patient depends on all of the following factors EXCEPT:
a- Life expectancy
b- Symptoms
c- Gleason score
d- Comorbid conditions
e- Disease stage
3 511
Prostate cancer pharmacological therapy may involve the use of many drugs. A patient diagnosed with castrate-refractory prostate cancer (CRPC). All the following can be indicated for the treatment of CRPC patients, EXCEPT:
a- Docetaxel
b- Radium-223
c- Apalutamide
d- Trastuzumab
e- Enzalutamide
3 511
What is the most common pathologic cell type of prostate cancer?
3 511
Which of the following is an effective method to decrease the tumor flare syndrome of prostate cancer associated with the first few weeks of LHRH agonist therapy?
a- Start the LHRH agonist with a loading dose to rapidly achieve steady-state levels
b- Start an antiandrogen before the LHRH agonist and continue for the first 3 to 4 weeks of therapy
c- Start the LHRH agonist with a 50% dose decrease, slowly titrating to a full dose over 3 to 4 weeks
d- Alternate LHRH agonists during the first 3 to 4 months of therapy
e- Maintain testosterone levels above castration levels
3 511
58-year-old male presented with a PSA of 17.9 ng/ml, T3 and Gleason 7 (3+4) and diagnosed with prostate adenocarcinoma as castration-resistant prostate cancer. Which of the following antiandrogens is FDA approved for castration-resistant prostate cancer and can be used as the first-line setting to delay the initiation of chemotherapy in both nonmetastatic and metastatic disease?
a- Bicalutamide
b- Enzalutamide
C- Nilutamide
d- Flutamide
e- Abiraterone
3 511
Adnan received some prostate cancer medications. All the followings medication can cause castration to him EXCEPT:
3 511
A patient was diagnosed to have locally invasive prostate cancer. Which one of the following symptoms is expected to be seen in this patient?
3 511
The followings are correct regarding the pathophysiology of prostate cancer EXCEPT
A- Well-differentiated tumors grow slowly.
B- Adenocarcinoma cells Include 95% of cases.
C- The kidney is the most organ Involved initially in metastasis
D- The rationale for hormone therapy is based on the effect of androgen on the growth and differentiation of the normal prostate
E- Localized prostate cancer is curable by surgery or radiotherapy
3 511
Regarding prostate cancer, which of the following maneuvers considered as a
non-pharmacological therapy for prostate cancer
3 511
Regarding management of prostate cancer. Which of the following regarding the combination of (flutamide and leuprolide) is true?
A- It is indicated to delay the initiation of chemotherapy in both nonmetastatic and metastatic disease.
B- It is indicated for advanced prostate cancer.
C- It is indicated for orchiectomy.
D- It is indicated for metastatic castrate-resistant prostate cancer.
E- It is indicated as adjuvant therapy before mastectomy.
3 511
Many hormones involve in regulating prostate gland function. Hormone (s) that involve in regulation of prostate gland function is/are:
